Resources (21-27 of 27)

1. [Illinois] Cancer Community Symposium 2012: Arginine Glycine Aspartic Acid Motif Peptide Potentiates the Effect of Oxaliplatin Preventing Colon Cancer Metastasis, Binds to α5 β1 Integrin and Suppresses FAK/ERK/NF-kB Signaling

   09 May 2012 | | Contributor(s):: Elvira de Mejia

   Arginine Glycine Aspartic Acid Motif Peptide Potentiates the Effect of Oxaliplatin Preventing Colon Cancer Metastasis, Binds to α5 β1 Integrin and Suppresses FAK/ERK/NF-kB SignalingLunasin is a promising chemopreventive agent. The objective was to study the effect of lunasin on human colon cancer...

2. [Illinois] Cancer Community Symposium 2012: A Sensitivity Scale for Targeting T Cells with Chimeric Antigen Receptors (CAR) and Bispecific T Cell Engagers (BiTE)

   09 May 2012 | | Contributor(s):: Jennifer Stone

   Using a patients immune system to target cancer and maintain long-term surveillance is an attractive goal. Although T cells can respond potently to tumors, immune tolerance mechanisms often result in deletion or inactivation of those T cells expressing specific T cell receptors (TCRs) against...

3. [Illinois] Cancer Community Symposium 2012: Micro-western Arrays for Identification of Novel Mechanisms Underlying Resistance of Cancer Cells to Chemotherapeutic Agents

   09 May 2012 | | Contributor(s):: Richard B. Jones

   A fundamental goal in cancer treatment is the delivery of therapeutics in a manner that takes into consideration genetic differences between individuals. Genome-wide association analyses have discovered many DNA variants that influence complex phenotypes such as response to anti-cancer...

4. [Illinois] Cancer Community Symposium 2012: DriveRank: Discovering Patient-Specific Driver Mutations

   09 May 2012 | | Contributor(s):: Jack Pu Hou

   One of the pressing challenges in cancer genomics is to distinguish driver mutations (i.e. mutations involved in tumorigenesis) and passenger mutations (i.e. functionally neutral mutations). Current approaches to identifying driver mutations in cancer look for recurrent events in multiple...

5. [Illinois] Cancer Community Symposium 2012: Elevated Estrogen Signaling Drives Tumorigenesis in a Novel Animal Model for Ovarian Epithelial Cancer

   09 May 2012 | | Contributor(s):: Mary Jo Laws

   We generated a mouse model where aberrant estrogen receptor alpha (Esr1) signaling in the hypothalamo-pituitary-ovarian axis leads to ovarian tumorigenesis. In this model, termed Esr1d/d, the Esr1 gene is selectively deleted in the anterior pituitary. The Esr1d/d mice form palpable ovarian tumors...

6. [Illinois] Cancer Community Symposium 2012: An Integrated Approach to Cancer Research

   09 May 2012 | | Contributor(s):: John F. McDonald

   The field of cancer biology is rapidly moving from an era of specialization to an era of integration. In my presentation, I will provide examples of the integration of molecular biology with analytical chemistry, computer science/machine learning and material science/nanotechnology to develop...

7. [Illinois] Cancer Community Symposium 2012: Closing Address and Awards

   09 May 2012 | | Contributor(s):: Rohit Bhargava

   Jaeyun Sung announces the awards from the poster sessions. Dr. Rohit Bhargava provides the audience with reflections on the conference and thoughts going forward.Cancer Community At Illinois Symposium 2012 April 5-6, 2012: Connecting patient care, research, and scientific advancementSymposium...